Corcept Therapeutics (CORT) ramps up another 15% today, rising for a second day following an...

|About: Corcept Therapeutics Incorp... (CORT)|By:, SA News Editor

Corcept Therapeutics (CORT) ramps up another 15% today, rising for a second day following an upgrade yesterday by Piper Jaffray and analysts at Janney Capital beginning coverage of the stock with a Buy rating and a $3 price target. CORT climbed just over 10% on Thursday to close at $1.63 a share, its best finish since early November.